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Embryonic and fetal stages of skeletal muscle development are characterized by the differential expression of a number of
muscle-speci®c genes. These include the products of independent promoters at the fast myosin light chain 1F/3F locus. In
the mouse embryo MLC1F transcripts accumulate in embryonic skeletal muscle from E9, 4±5 days before high-level
accumulation of MLC3F transcripts. A 3* enhancer can activate MLC1F and MLC3F promoters in differentiated muscle
cells in vitro and in transgenic mice; both promoters, however, are activated at the time of MLC1F transcript accumulation.
We now demonstrate the presence of a second muscle-speci®c enhancer at this locus, located in the intron separating the
MLC1F and MLC3F promoters. Transgenic mice containing the intronic, but lacking the 3* enhancer, express high levels
of an nlacZ reporter gene from the MLC3F promoter in adult fast skeletal muscle ®bers. In contrast to the 3* enhancer,
the intronic element is inactive both in embryonic muscle cells in vivo and in embryonic myocyte cultures. The intronic
enhancer is activated at the onset of fetal development in both primary and secondary muscle ®bers, at the time of
endogenous MLC3F transcript accumulation. Late-activated MLC3F transgenes thus provide a novel in toto marker of fetal
myogenesis. These results suggest that temporal regulation of transcription at the MLC1F/3F locus is controlled by separate
enhancers which are differentially activated during embryonic and fetal development. q 1997 Academic Press
INTRODUCTION embryonic and fetal myogenesis (Lyons and Buckingham,
1992; Stockdale, 1992). A major regulatory step in the gener-
ation of cell-type, spatial and temporal diversity in skeletalCoordinated development requires precise temporal and
muscle is control at the level of transcription. Dissectionspatial control of gene expression, regulating the properties
of the in vivo role of skeletal muscle enhancers and promot-of diverse cell types during embryogenesis. Striated skeletal
ers in transgenic mice has resulted in the de®nition of cis-muscle provides a model system for analysis of the genetic
acting elements which control ®ber-type-speci®c expres-control of these processes. Adult skeletal muscle is a hetero-
sion or confer distinct transcriptional properties on rostral,geneous tissue composed of several cell-types with distinct
caudal, and individual muscles (Concordet et al., 1993; Hal-biochemical and contractile properties (Kelly and Rubin-
lauer et al., 1993; Banerjee-Basu and Buonanno, 1993; Levitt
stein, 1994). In addition, muscles differ along the body axis,
et al., 1995; Donoghue et al., 1991; Patapoutian et al., 1993).
de®ning the spatial and functional identity of muscle groups In this study we de®ne a developmentally regulated en-
and individual muscles throughout the body (Donoghue and hancer which is active in adult and fetal, but not embryonic,
Sanes, 1994); this diversity originates in the embryo where skeletal muscle.
muscle genes are expressed in a dynamic pattern during The expression pro®les of members of the alkali myosin
light chain (MLC) gene family illustrate the diverse patterns
of muscle-speci®c gene expression in vivo (Barton and Buck-1 Present address: Biology Faculty, University of Konstanz, D-
ingham, 1985). In birds and mammals, the MLC1F/3F gene78434 Konstanz, Germany.
encodes two MLC isoforms found in developing and adult2 Present address: Inserm U382, Luminy, Marseilles, France.
fast muscle ®bers, MLC1F and MLC3F, which differ in the3 Present address: Walter and Eliza Hall Institute of Medical Re-
N-terminal region due to the use of two promoters and asearch, Royal Melbourne Hospital, Victoria 3050, Australia.
subsequent alternative splicing event (Nabeshima et al.,4 To whom correspondence should be addressed. E-mail: margab@
pasteur.fr. Fax: 33-1-40613452. 1984; Periasamy et al., 1984; Robert et al., 1984). MLC3F
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site, nlacZ-SV40poly(A) in frame in the second MLC3F-speci®ctranscripts are also found in cardiac muscle (Kelly et al.,
exon and 1 kb of MLC3F sequence 3* of nlacZ in pBluescript (Stra-1995). In skeletal muscle, MLC1F and MLC3F isoforms ap-
tagene). p3F-nlacZ-2E (Kelly et al., 1995) contains the 3* enhancerpear at distinct times during embryogenesis: in the mouse,
at the 3* end of the insert of p3F-nlacZ-2 (in the genomic orientationMLC1F transcripts accumulate from E9 when embryonic
relative to the MLC3F promoter). p3F-nlacZ-2 was extended to 09skeletal muscle ®rst differentiates in the myotomal com-
kb: pH1-BH was derived from pH1 containing the ®rst intron and
partment of somites, whereas MLC3F transcripts accumu- MLC1F promoter region of the mouse MLC1F/3F gene (Robert et
late at a high level in fetal skeletal muscle from E13.5 to al., 1984) by cloning intronic sequences from a BamHI site 3* to
E15 (Lyons et al., 1990; Ontell et al., 1993). This temporal exon 1 to the HindIII site at 02 kb (7 kb) into pBluescript; p3F-
difference in mRNA accumulation is due to uncoupled tran- nlacZ-2 was digested with KpnI and partially with HindIII. The
largest (7 kb) KpnI±HindIII fragment was ligated into KpnI±HindIII-scription at the MLC1F and MLC3F promoters, suggesting
digested pH1-BH to generate p3F-nlacZ-9. Deletions between 09that they respond to different developmental cues (Cox and
and 02: the 14-kb insert of p3F-nlacZ-9 was isolated on a SacII±Buckingham, 1992). It has been shown that the two promot-
KpnI fragment and digested partially with Sau3A to generate p3F-ers are functionally independent in muscle cells in culture
nlacZ-5.8 and p3F-nlacZ-5. p3F-nlacZ-5 was digested with NotI(Strehler et al., 1985; Daubas et al., 1988; Seidel and Arnold,
and SalI, blunt-ended, and religated to generate p3F-nlacZ-4.2. The1989; Pajak et al., 1991), and that MLC1F and MLC3F gene
region between 04.2 and 05 kb upstream of the MLC3F transcrip-
products accumulate differently in response to innervation tion initiation site (p800) was subcloned from p3F-nlacZ-5 by diges-
(Merri®eld and Konigsberg, 1987; Barton et al., 1989). tion with SalI and SmaI, ®lling in with Klenow polymerase, dilu-
The MLC1F/3F gene is therefore of interest in de®ning tion, and religation, to delete all insert sequences 3* of 04.2 kb;
cis-acting sequences which regulate the transcriptional con- this plasmid was digested with KpnI and ligated to the 7-kb KpnI
insert of p3F-nlacZ-2 to generate p3F-nlacZ-2I. p3F-nlacZ-9 wastrol of skeletal muscle diversity. An enhancer 3* to the
digested with PstI and a 13.8-kb fragment religated to generate p3F-MLC1F/3F gene confers high-level expression from the
nlacZ-9D(06:02.8). The 13.8-kb fragment was ligated to a 2.7-kbMLC1F promoter in skeletal muscle cells in culture and in
PstI fragment containing the sequence between 05.5 and 02.8 kbtransgenic mice, where it is active by E9.5 in the myotome,
to generate p3F-nlacZ-9D(06:05.5) (containing one copy of the se-and E11.5 in forming limb muscles, coincident with endoge-
quence between 05.5 and 02.8 in the genomic orientation), andnous MLC1F transcript accumulation (Donoghue et al.,
p3F-nlacZ-9D(06:05.5)rev (containing this sequence in the reverse
1988; Rosenthal et al., 1989; Grieshammer et al., 1992). We orientation).
previously addressed the question of how a single enhancer (ii) TK-CAT constructs. The 800-bp intronic enhancer was
can regulate two independent promoters by investigating subcloned in forward and reverse orientations upstream of the her-
the role of this element on transcription from the MLC3F pes simplex virus thymidine kinase (TK) promoter in pBLCAT2
(Luckow and SchuÈ tz, 1987). The SalI±KpnI insert of pBLCAT2 waspromoter in transgenic mice. The 3* enhancer precociously
subcloned into p3F-nlacZ-5 digested with SalI and KpnI to generateactivates MLC3F transcription in skeletal muscle at the
pI-TK-CAT. An 800-bp SalI±SacII fragment from p3F-nlacZ-5 wastime of MLC1F promoter activation, and therefore does not
digested with Sau3A and ligated into SalI/BamHI-digestedconfer correct developmental speci®city on the MLC3F pro-
pBLCAT2 to generate pIrev-TK-CAT.moter in vivo, nor does this speci®city reside in the pro-
moter itself (Kelly et al., 1995).
How, then, is temporal regulation of MLC3F transcrip- Cell Culture and Transfections
tion controlled? We report here the identi®cation of a sec-
C2/7 cells were cultured and transfected at the myoblast stageond skeletal muscle-speci®c enhancer within the ®rst in-
as described in Kelly et al. (1995). Myoblasts were harvested 24 hrtron of the mouse MLC1F/3F gene. In transgenic mice both
posttransfection and myotubes 2±3 days after switching the cellsMLC1F/3F enhancers are active in adult skeletal muscle;
to differentiation medium (2% fetal calf serum). NIH 3T3 ®bro-this novel element, however, does not function in embry-
blasts were cultured in 7% fetal calf serum in DMEM and trans-onic muscle cells (E9±E13.5), and activates transgene ex-
fected as for C2/7 cells, except at elevated con¯uency (approxi-
pression during fetal myogenesis (E13.5±birth), coincident mately 75%). Primary embryonic cultures were prepared from
with high-level accumulation of the endogenous MLC3F E11.5 limb buds as described by Cusella-De Angelis et al. (1994).
transcript. These results demonstrate that distinct spatio- b-Galactosidase assays were performed on 0.2±7% of cell extract
temporal patterns of skeletal muscle gene expression during (from a 6-cm culture dish) as described in Sambrook et al. (1989),
and using a chemiluminescent reporter assay (GalactoLight,development can be mediated by different enhancers at one
Tropix, Bedford, MA) following the manufacturer's instructionslocus and provide novel insights into skeletal muscle diver-
(Jain and Magrath, 1991). Luminescence was measured on asi®cation during development.
Berthold luminometer (Model LB-9501). CAT assays were per-
formed on 0.2±5% of cell extract (Biben et al., 1994). b-Galactosi-
dase and CAT values were normalized for transfection ef®ciency
METHODS by evaluating luciferase activity from a cotranfected RSVluciferase
vector (10±20% cell extract; Biben et al., 1994). Values shown rep-
resent the mean plus standard error of the mean (SEM) of at leastPlasmid Constructions
four experiments with more than one plasmid preparation for each
construct. Student's t test was used to evaluate whether differences(i) 3F-nlacZ constructs. Plasmid(p) p3F-nlacZ-2 (Kelly et al.,
1995) contains 2 kb upstream of the MLC3F transcriptional start between mean values were signi®cant.
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Generation of Transgenic Mice Oligonucleotides
(1) 5*-TGTCTGTAGAAGTCATTC-3*; (2) 5*-AAGGAGTAA-3F-nlacZ-2E transgenic mice are described in (Kelly et al., 1995).
AGTAGGTG-3*; (3) 5*-TTTTCTCGCCCAACCAGAA-3*; (4) 5*-The insert of p3F-nlacZ-9 was excised as a KpnI±SacII or BamHI
GTCTCTGGCACAGATTTAATTA-3*.fragment; the inserts of p3F-nlacZ-2, and p3F-nlacZ-2I were excised
as KpnI and SacII±BamHI fragments, respectively. Fragments for
microinjection were puri®ed by gel electrophoresis and passage
through an Elutip column (Schleicher and Schuell). Transgenic RESULTS
mice were generated by microinjection of puri®ed DNA fragments
into fertilized (C57BL/6J 1 SJL) F2 eggs at concentrations of 700± A Second Muscle-Speci®c Enhancer Element at the1000 copies/pl using standard techniques (Hogan et al., 1994). In-
Mouse MLC1F/3F Locusjected eggs were reimplanted into pseudopregnant (C57BL/6J 1
CBA) F1 foster mothers. In transgenic mice the 3* enhancer activates both MLC1F
and MLC3F promoters from E9, 4 days before high-level
transcription from the endogenous MLC3F promoter (Gries-
Identi®cation and Analysis of Transgenic Mice hammer et al., 1992; Kelly et al., 1995). We initiated a
search for additional cis-acting DNA elements which might
Transgenic mice were identi®ed as described in Kelly et al.
regulate late transcription from the MLC3F promoter. A(1995); all except 3F-nlacZ-2 lines could be identi®ed by in toto X-
series of plasmid constructs were generated containinggal staining of skinned tails. Transgene expression was analyzed as
mouse MLC1F/3F sequences including the MLC3F pro-described (Kelly et al., 1995). Anti-fast and neonatal myosin heavy
moter upstream of an Escherichia coli lacZ gene with achain (MHC) (MY32, Sigma), anti-sarcomeric MHC (MF20; Bader
nuclear localization signal (nlacZ) fused to the ®rst 8 aminoet al., 1982), and anti-b-galactosidase antibodies were applied to
cryostat sections as described in Tajbakhsh and Buckingham (1995). acids of the MLC3F coding sequence (Fig. 1a; Kelly et al.,
Transgene copy number was determined using a Phosphorimager 1995). Of particular interest was the 10-kb intron separating
(Molecular Dynamics). b-Galactosidase activity in transgenic mice the MLC1F and MLC3F promoters, since an analysis of
was quanti®ed as follows: adult tissues were dissected into 300 ml DNase I-hypersensitive sites at the MLC1F/3F locus in C2/
of TGD (0.25 M Tris±HCl (pH 7.5), 15% glycerol, 10 mM DTT) on 7 muscle cells had revealed the presence of at least one
ice and homogenized for 15 sec using a polytron Tissumizer at
differentiation-speci®c DNase I-hypersensitive site within80% maximum power (Tekmar, Cincinnati, OH). Three hundred
this intron, in addition to a site at the 3* end of the genemicroliters of lysis buffer (GalactoLight, Tropix) plus 1 mM DTT,
(data not shown). On transient transfection into C2/7 cells,0.2 mM PMSF, and 5 mg/ml leupeptin was added and the samples
a construct containing 9 kb of intronic sequence upstreamcentrifuged for 5 min at 15,000 rpm. The supernatant was incubated
of the MLC3F transcriptional start site (3F-nlacZ-9) was 25-at 487C for 1 hr to inactivate endogenous b-galactosidase activity,
the protein concentration was measured using a Bio-Rad protein fold more active in differentiated myotubes than a 02 kb
assay (Bio-Rad, Munich, Germany), and 1 mg of extract was assayed MLC3F promoter (3F-nlacZ-2; Fig. 1a). This result suggests
in duplicate for b-galactosidase activity for 60 min at room temper- that there is a second MLC1F/3F enhancer within this 7-
ature using the chemiluminescent reporter assay described above. kb intronic sequence.
Activity was expressed as relative light units (rlu)/60 min/mg of In order to delimit this regulatory element, sequences
extract. A standard concentration series of puri®ed b-galactosidase
between 09 and 02 kb upstream of the ®rst MLC3F exon(714 U/mg, Sigma) was routinely included to evaluate assay linear-
were sequentially deleted and reporter gene activity assayedity and reproducibility.
in C2/7 myotubes. Activity dropped to 50% that of 3F-
nlacZ-9 on progressive deletion from 09 to 05 kb (Fig. 1a);
activity then dropped sharply to the level of the 3F-nlacZ-In Situ Hybridization
2 on deletion to 04.2 kb (compare 3F-nlacZ-5 and 04.2),
suggesting that at least 50% of the activity of the intron liesRNA±RNA hybridization was performed as described in Kelly
in the 800-bp sequence from 04.2 to 05 kb. When placedet al. (1995). Antisense riboprobes used were from the ®rst MLC1F/
3F intron (Kelly et al., 1995), the MLC1F 5*UTR (Lyons et al., upstream of the 02-kb promoter, the 800-bp sequence en-
1990), and a 61-nt MLC3F antisense riboprobe containing 25 nt hances transcription with approximately 60% of the activ-
complementary to each MLC3F-nlacZ-speci®c exon (2 and 3, Fig. ity of the entire intron (3F-nlacZ-2I, Fig. 1a). Deletion of a
1a), and 11-nt complementary to exon 4 (details to be published 3.2-kb fragment within the ®rst intron, including the 05
elsewhere). to 04.2 kb region, reduces activity to that of 3F-nlacZ-2;
reintroduction of a 2.7-kb fragment containing the 800-bp
sequence in either orientation restores enhancer activity
DNA Sequence Analysis (Fig. 1a). The intronic element is therefore able to enhance
transcription from the MLC3F promoter in a position- andThe 800-bp enhancer element from the MLC1F/3F ®rst intron
orientation-independent manner.was sequenced using an Auto Read sequencing kit (Pharmacia, Up-
Transient transfections into C2/7 myoblasts and NIHpsala, Sweden) using oligonucleotide primers 1±4 in addition to
3T3 ®broblasts were carried out to assess the cell-type speci-M13 forward and reverse primers; reaction products were separated
using an automated ALF DNA sequencer (Pharmacia). ®city of the intronic enhancer. Reporter gene expression
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levels were compared to that of a Rous sarcoma virus pro- The 3* enhancer has been previously demonstrated to be a
moter (RSVlacZ). Whereas the activity of 3F-nlacZ-9 is ap- strong positive regulatory element in adult skeletal muscle
proximately equivalent to that of RSVlacZ in myotubes, it (Rosenthal et al., 1989; Kelly et al., 1995). Transgenic mice
is approximately 200 times less than RSVlacZ in myoblasts carrying the intronic enhancer also display a high level of
(Fig. 1a) and 40 times less in NIH 3T3 ®broblasts (data not reporter gene expression in adult muscle: 3F-nlacZ-9 and
shown). Similar results were obtained with the 02 kb pro- 3F-nlacZ-2I transgenic mice exhibit a comparable level and
moter plus either the intronic enhancer (3F-nlacZ-2I) or the cell-type speci®city of b-galactosidase activity to 3F-nlacZ-
3* enhancer (3F-nlacZ-2E) (Fig. 1a), demonstrating that both 2E mice on whole-mount X-gal colouration of individual
enhancers are active at a high level speci®cally in differenti- muscles (Fig. 2a). Quantitative analysis of transcriptional
ated muscle cells. The activity of the 800-bp sequence was activity per microgram of tissue extract using a chemilumi-
tested on a heterologous promoter, the HSV thymidine ki- nescent assay (Jain and Magrath, 1991; Shaper et al., 1994)
nase (TK) promoter driving expression of a CAT reporter showed that transgenic mice containing either the intronic
gene. The intronic enhancer, in either orientation upstream (3F-nlacZ-9) or the 3* enhancer (3F-nlacZ-2E) have high b-
of the TK promoter, increases CAT activity approximately galactosidase activities in adult skeletal muscle (quanti®ed
10-fold over the promoter alone (Fig. 1b), showing that the in extensor digitorum longus (EDL), soleus and masseter),
activity of the intronic enhancer is not promoter speci®c. and background activities in a control tissue, kidney (Figs.
The DNA sequence of the 800-bp intronic enhancer is pre- 2b and 2c). These transgenes are also expressed in the myo-
sented in Fig. 1c. This element contains a number of consen- cardium (left ventricle), a site of low-level endogenous
sus binding motifs for transcription factors found in other MLC3F expression (Kelly et al., 1995). In contrast, only two
muscle-speci®c regulatory elements, including 6 E-boxes, of four lines of 3F-nlacZ-2 transgenic mice containing the
the target sites of myogenic basic-helix±loop±helix (bHLH) 02-kb MLC3F promoter express nlacZ (lines 5 and 8), and
transcription factors (Weintraub et al., 1991), and several in these mice expression is con®ned largely to the heart
A/T-rich stretches (Fig. 1c). (Fig. 2d), where activity is comparable to that seen with
either enhancer. X-gal treatment of whole-mount muscles
from 3F-nlacZ-2 mice reveals extremely low-level and
Comparative Analysis of the Intronic and 3* patchy b-galactosidase activity in skeletal muscle ®bers,
Enhancers in Transgenic Mice although higher levels of expression are observed in a subset
of muscles of the head and neck, including regions of theThe above results establish the presence of a second en-
masseter (data not shown). These data demonstrate (i) thathancer at the mouse MLC1F/3F locus which drives high-
the intronic enhancer confers high level transgene expres-level MLC3F transcription in vitro. What is the role of this
sion in adult skeletal muscle in the absence of the 3* en-element in vivo? Transgenic mice containing the intronic
hancer, and (ii) that while MLC1F/3F sequences includedelement upstream of the MLC3F promoter and nlacZ re-
in 3F-nlacZ-2 effect transcription in cardiac muscle, theporter gene (3F-nlacZ-9 and 3F-nlacZ-2I) were generated and
MLC3F promoter does not support signi®cant transgene ex-the b-galactosidase expression pattern was compared with
pression in the majority of skeletal muscles in vivo.that of transgenes containing the MLC3F promoter plus 3*
The MLC3F isoform is speci®c to fast ®bers in adult skel-enhancer (3F-nlacZ-2E) or the MLC3F promoter alone (3F-
etal muscle. b-Galactosidase expression was assayed in twonlacZ-2). Transgene constructs and expression pro®les are
hindlimb muscles of adult transgenic mice: the EDL, whichsummarized in Table 1; for each construct at least two inde-
contains fast glycolytic type IIB ®bers, and the soleus, whichpendent lines were analyzed. We present our ®ndings with
contains slow type I and fast oxidative type IIA ®bers (Schi-respect to (i) the level and cell-type speci®city of transgene
af®no and Reggiani, 1996). The level of transgene expressionexpression in adult muscle and (ii) the spatiotemporal pat-
in the soleus of 3F-nlacZ-9 transgenic mice is 8- to 10-foldtern of transgene expression during embryonic and fetal my-
ogenesis. lower than in the EDL (Fig. 2b), and we therefore conclude
FIG. 1. Two skeletal muscle enhancers at the mouse MLC1F/3F locus. (a) Structure of the locus showing 3F-nlacZ reporter gene constructs
and activity in C2/7 myotubes and myoblasts. Independent MLC1F and MLC3F promoters generate transcripts with differential 5* splicing
patterns; the positions of the 3* (E, open box) and intronic enhancers (I, shaded box) are indicated. Construct nomenclature refers to the
5* limit of each construct with respect to the MLC3F transcription start site. Mean b-galactosidase activities plus SEM are expressed
relative to that of 3F-nlacZ-9 (set arbitrarily at 100 for myotubes). (b) Activity of the intronic enhancer on transcription from a heterologous
promoter (TK) in C2/7 myotubes; CAT activities (mean plus SEM) are presented relative to TK-CAT (set arbitrarily at 10). (c) DNA
sequence of the 800-bp intronic enhancer. The sequence extends from 05 to 04.2 kb upstream of the MLC3F transcriptional start site
(EMBL Accession No. Y08458). E-box target motifs for myogenic bHLH proteins (boxed) and an A/T-rich sequence containing a single
mismatch with a MEF2 site in the 5* enhancer of the M-creatine kinase gene (shaded box) are indicated (Gosset et al., 1989). Open arrows,
transcriptional start sites; Ð, MLC1F and ± ±, MLC3F splice patterns; rev, intronic enhancer in reverse orientation; D(6:2.8), internal
intronic deletion from 06 to 02.8 kb upstream of the ®rst MLC3F exon; D(6:5.5), internal intronic deletion from 06 to 05.5 kb.
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TABLE 1
MLC3F Transgenes: Expression in Striated Muscle
Transgene Transgene Embryonic (E12.5) Fetal (E16.5) Adult
/ve F0 copy
Construct mice Lines number Skeletal Cardiac Skeletal Cardiac Skeletal Cardiac
3F-nlacZ-9 1a 9-a 2 0 / / / / /
9-b 4 0 / / / / /
3F-nlacZ-21 2 2I-1 nd 0 / / / / /
2I-27 nd 0 / / / / /
3F-nlacZ-2E 2 2E-1 7 / / / / / /
2E-2 7 / / / / / /
3F-nlacZ-2 5b 2-5 8 0 / 0 / 0c /
2-8 18 0 / 0 / 0c /
2-10 50 0 0 0 0 0 0
2-11 30 0 0 0 0 0 0
Note. nd, not determined.
a Lines 9-a and 9-b were derived from a single 3F-nlacZ-9 F0 mouse (transmission frequencies: 9-a, 49/79 F1 mice; 9-b, 4/79 F1 mice).
Two independent F0 3F-nlacZ-9 embryos were analyzed at E14.5 and showed an expression pro®le comparable to that in Fig. 5d.
b One 3F-nlacZ-2 F0 mouse did not transmit the transgene (0/38 F1 mice); in this mouse no transgene expression was observed in adult
tissues.
c Signi®cant b-galactosidase activity was observed in these lines only in a subset of muscles of the head and neck (data not shown).
that the transgene is expressed at a higher level in fast IIB level reporter gene expression in 1F-CAT-E mice (100-fold
less than EDL, Donoghue et al., 1991), expresses nlacZ atthan in IIA and slow ®bers. 3F-nlacZ-2I mice display a simi-
lar ®ber-type distribution, as does the 3F-nlacZ-2E a high level in 3F-nlacZ-9 and 3F-nlacZ-2E mice, suggesting
that these constructs do not confer a gradient of transgenetransgene which is down-regulated in muscles with reduced
contributions of fast IIB ®bers (Fig. 2c; Kelly et al., 1995). activity (Figs. 2b and 2c). Furthermore, no gradient of re-
porter gene activity was observed across the intercostalSince both the intronic and 3* enhancers confer a similar
®ber-type distribution on the MLC3F promoter, ®ber-type muscles of MLC3F transgenic mice containing either en-
hancer (constructs 3F-nlacZ-2E, 3F-nlacZ-9, and 3F-nlacZ-restrictive elements may be present in the 02-kb promoter
region. 2I; data not shown). Elements responsible for graded expres-
sion are therefore likely to lie outside the sequences in-A rostrocaudal gradient of CAT activity has been ob-
served in 1F-CAT-E and 1F-lacZ-E transgenic mice (Do- cluded in these 3F-nlacZ constructs.
noghue et al., 1991; Rao et al., 1996). No positional gradient
of nlacZ transcripts was observed in 3F-nlacZ-2E transgenic
The 3* but Not the Intronic Enhancer Is Active inmice (Kelly et al., 1995). McGrew et al. (1996), however,
Embryonic Skeletal Musclereported graded reporter gene expression in 3F-CAT-E and
3F-CAT transgenic mice, suggesting that redundant cis ele- Myogenesis in utero occurs in two waves: embryonic (E9±
E13.5) and fetal (E13.5±birth), which result in the formationments at this locus may contribute to graded expression.
We therefore investigated whether nlacZ expression was of primary and secondary myotubes, respectively (Kelly and
Zacks, 1969; Ontell and Kozeka, 1984; Ross et al., 1987).positionally graded in transgenic mice containing the in-
tronic enhancer. The masseter, a rostral muscle with low- The ®rst embryonic skeletal muscle cells arise in the myo-
FIG. 2. MLC3F transgene expression in adult tissues. (a) Representative X-gal-treated extensor digitorum longus (EDL) muscles from
adult MLC3F transgenic mice containing no enhancer (3F-nlacZ-2), the 3* enhancer (3F-nlacZ-2E), or the intronic enhancer (3F-nlacZ-2I
and 3F-nlacZ-9); dissected muscles were ®xed and stained for b-galactosidase activity in parallel. Mean b-galactosidase activities plus
SEM are shown for various adult tissues of transgenic lines containing constructs 3F-nlacZ-9 (b), 3F-nlacZ-2E (c), and 3F-nlacZ-2 (d).
Activities are expressed on a logarithmic scale as relative light units (rlu) per microgram of protein extract puri®ed from skeletal muscle
(EDL, soleus (SOL) and super®cial masseter (MASS)), kidney (KID), and left ventricular cardiac muscle (LV). At least four adult (2±6
months) heterozygotes were assayed per line (two adults for 3F-nlacZ-2 lines). EDL and SOL values were determined in duplicate for each
animal and represent the mean and SEM of at least 8 muscles (4 for 3F-nlacZ-2 lines). Background b-galactosidase activities in nontransgenic
adult mice are indicated by broken lines and represent high and low extremes (KID and EDL, respectively). 2, 3F-nlacZ-2; 2E, 3F-nlacZ-
2E; 2I, 3F-nlacZ-2I; 9, 3F-nlacZ-9. Scale bar: 1 mm.
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tomal compartment of the somite at E9. The 3F-nlacZ-2E cultures isolated from 3F-nlacZ-9 limb buds, myocyte nu-
clei were b-galactosidase negative (Figs. 4a and 4b). Weaklytransgene is expressed in the myotome at this stage, 4 days
before high-level transcription from the endogenous MLC3F positive nuclei were occasionally detected in these cultures
after 4±5 days of differentiation. In contrast, nuclei of 3F-promoter, and at the time of activation of the MLC1F pro-
moter (Fig. 3b; Kelly et al., 1995). The 3F-nlacZ-2E nlacZ-2E myocytes invariably contained b-galactosidase
positive nuclei after 48 hr (Figs. 4c and 4d). The intronictransgene is also expressed in the developing heart. At E12.5
3F-nlacZ-2E transgene expression extends throughout the enhancer therefore remains inactive in embryonic muscle
cells cultured in vitro; MLC3F transgene expression in theseembryonic skeletal musculature (Figs. 3e and 3h). Strik-
ingly, despite the presence of the intronic enhancer which cells appears to be dependent on the 3* enhancer.
is active in adult skeletal muscle, the reporter gene in 3F-
nlacZ-9 mice is not transcribed in embryonic skeletal mus-
cle; at E10.5 the 3F-nlacZ-9 transgene is expressed in the The Intronic Enhancer Is Activated during Fetal
heart, but not in differentiated skeletal muscle cells (Fig. Development
3a). The 3F-nlacZ-9 transgene is also expressed ectopically
in the nervous system, notably in dorsal root ganglia which The experiments described above demonstrate that the
intronic enhancer activates transgene expression in adult¯ank the neural tube along the axis of the embryo, adjacent
to, but distinct from, the myotome (Figs. 3a, 3d, and 3g). but not embryonic skeletal muscle. The expression pro®les
of different transgenic lines were subsequently analyzedTwo days later (E12.5) there is still no detectable expression
in embryonic skeletal muscle, although transgene activity during the second, fetal, phase of in utero myogenesis. The
intronic enhancer becomes active in skeletal muscle duringpersists in the heart and nervous system (Figs. 3d and 3g).
Similar results are observed with the 3F-nlacZ-2I transgene this stage of development; expression of 3F-nlacZ-9 and 3F-
nlacZ-2I transgenes in skeletal muscle is observed from(results not shown). In the absence of either enhancer, the
MLC3F promoter is not expressed in embryonic skeletal E13.5, appearing initially at a low level in particular mus-
cles, including the cervical and thoracic domains of the de-muscle (Figs. 3c, 3f, and 3i). Several sites of ectopic expres-
sion are seen in MLC3F transgenic mice: 3F-nlacZ-9 and veloping trapezius muscle (Fig. 5a). In 3F-nlacZ-9 line 9-b
mice (which express the transgene at a higher level than3F-nlacZ-2I transgenic mice express nlacZ in the roof plate
of the neural tube and choroid plexus (Figs. 3a, 3d, and 5a). line 9-a mice) low-level expression is already detectable in
a triangular (presumed forming trapezius) muscle in the cer-Transgene-expressing 3F-nlacZ-2 lines have b-galactosidase
activity in dorsal mesenchymal cells in the forelimb region, vical region at E12.5 (data not shown). In contrast, no skele-
tal muscle expression is observed in transgene expressingand at a low level in dorsal root ganglia (Figs. 3c, 3f, and
5b); expression persists postnatally in the fascia of certain 3F-nlacZ-2 lines at E13.5 (Fig. 5b). 3F-nlacZ-9 and 3F-nlacZ-
2I transgene expression increases rapidly from E13.5, ini-forelimb muscles. In addition, all MLC3F transgenic lines
analyzed express b-galactosidase in the dorsal otic vesicle tially in muscles adjacent to the developing trapezius in-
cluding the deltoid muscle, extensor muscles of the fore-(Kelly et al., 1995). Elements responsible for expression at
sites shared by independent transgenic lines are presumably limb, and the latissimus dorsi (Figs. 5d and 5e). The 3* en-
hancer is active in the majority of skeletal muscles at theuncovered in the transgenes, and silenced at the MLC1F/
3F locus, since none are sites of endogenous MLC3F expres- same stage (Figs. 5c and 5f). A similar pro®le of late
transgene activation was observed in two F0 3F-nlacZ-9sion (as assessed by in situ hybridization, data not shown).
MLC3F transgene expression pro®les in embryos prior to mice analyzed at E14.5 (data not shown). Histological analy-
sis con®rms that 3F-nlacZ-9 transgenes are expressed inE13 thus demonstrate that of the two enhancers which acti-
vate the MLC3F promoter in adult skeletal muscle, only only a subset of muscles which express 3F-nlacZ-2E trans-
genes at E14.5 (Figs. 6a and 6b). Endogenous MLC3F andthe 3* enhancer is functional in embryonic muscle. We con-
clude that activity of the intronic enhancer is temporally MLC1F transcripts were localized in fetal skeletal muscles
by in situ hybridization. MLC3F transcripts are detectableregulated during skeletal muscle development.
Embryonic myoblasts can be cultured in vitro where they at a low level in the majority of skeletal muscles at E15.5,
but accumulate at a higher level in particular musclesdifferentiate as mono- or oligonucleated myocytes, and have
distinct properties from myoblasts isolated at later stages which are also those where the intronic enhancer is ®rst
activated (Fig. 6c); MLC1F transcripts, in contrast, are pres-of development (Vivarelli et al., 1988; Smith and Miller,
1992). We investigated whether the intronic enhancer ent at an equivalent level in different muscles (Fig. 6d).
Differential activation of MLC3F transgenes in the presencewould be inactive in embryonic myocytes when they differ-
entiate outside the embryonic environment. Primary my- of either the 3* or intronic enhancer therefore re¯ects the
differential accumulation of endogenous MLC1F andoblast cultures were prepared from limb buds of E11.5
transgenic embryos and transgene expression analyzed after MLC3F transcripts. In the next 4 days of fetal development
the majority of skeletal muscles activate the 3F-nlacZ-9myocyte differentiation. After 48 hr cultures were ®xed and
assayed for myosin heavy chain (MHC) and b-galactosidase transgene such that by E18.5 expression is comparable to
that of 3F-nlacZ-2E mice (Fig. 7). Whole-mount X-gal stain-expression by immunocytochemistry. Numerous differenti-
ated MHC-positive myocytes were observed in all cases. In ing of 3F-nlacZ-9 and 3F-nlacZ-2I transgenes thus reveals
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FIG. 3. The intronic enhancer is inactive in embryonic muscle in vivo. Representative transgenic embryos stained in whole-mount with
X-gal for constructs 3F-nlacZ-9 (a and d), 3F-nlacZ-2E (b and e) and 3F-nlacZ-2 (c and f). At E10.5 only the 3F-nlacZ-2E transgene (b) is
active in the myotomal compartment (M) of the developing somites. The 3F-nlacZ-9 (a) and 3F-nlacZ-2 (c) transgenes are expressed in
myocardium (H) and ectopically in the nervous system, but not in the myotome. At E12.5 3F-nlacZ-9 (d) and 3F-nlacZ-2 mice (f) still do
not express the transgene in skeletal muscle, whereas the 3F-nlacZ-2E (e) transgene is widely expressed in embryonic muscle. Transverse
cryostat sections through representative E12.5 embryos show b-galactosidase expression in skeletal muscle (M) of 3F-nlacZ-2E mice (h)
but not 3F-nlacZ-9 (g) or 3F-nlacZ-2 mice (i), although the 3F-nlacZ-9 transgene is expressed in dorsal root ganglia (DRG) and the roof-
plate of the neural tube (RP). CP, forming choroid plexus; SG, semilunar ganglia; FL, nlacZ-expressing mesenchymal cells in the forelimb
region of 3F-nlacZ-2 mice; B, brain; OV, otic vesicle. Scale bars: 200 mm.
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FIG. 4. The intronic enhancer is inactive in embryonic myocytes in culture. Double immuno¯uoresence analysis of embryonic myocytes
derived from myoblasts isolated from E11.5 limb buds of 3F-nlacZ-9 (a and b) and 3F-nlacZ-2E (c and d) transgenic embryos. After 48 hr
in culture cells were ®xed and stained with antibodies to detect sarcomeric myosin heavy chain (MHC) (a and c) and b-galactosidase (b
and d). Whereas all 3F-nlacZ-2E-derived myocytes express the transgene, no b-galactosidase-positive nuclei are observed in 3F-nlacZ-9
myocytes. Scale-bar: 50 mm.
a dynamic pro®le of skeletal muscle gene activation during myosin heavy chain (MHC) isoforms. In the tibialis anterior
at E17.5 small secondary ®bers can be observed surroundingfetal development.
3F-nlacZ-9 and 3F-nlacZ-2I transgene activation during fe- large centrally nucleated primary ®bers. b-Galactosidase-
positive nuclei could be detected in both primary and second-tal myogenesis is coincident with extensive secondary myo-
tube formation. We investigated whether fetal transgene acti- ary ®bers of 3F-nlacZ-9 mice (Fig. 8), showing that the in-
tronic enhancer is activated in both myotube populations atvation was exclusive to secondary myo®bers using antibod-
ies to detect b-galactosidase and perinatal and adult fast the time of secondary ®ber formation.
FIG. 5. The intronic enhancer is activated during fetal development. Representative transgenic embryos stained in whole-mount with
X-gal for constructs 3F-nlacZ-9 (a and e), 3F-nlacZ-2 (b), 3F-nlacZ-2E (c and f), and 3F-nlacZ-2I (d). 3F-nlacZ-9 transgene expression initiates
in the developing trapezius muscle at E13.5 (a, arrowheads); ectopic expression persists in the nervous system. At E13.5 the 3F-nlacZ-2
transgene is inactive in skeletal muscle (b), whereas the 3F-nlacZ-2E transgene is expressed throughout the embryonic musculature (c).
At E14.5 MLC3F transgenes containing the intronic enhancer are more extensively expressed in skeletal muscles (d, 3F-nlacZ-2I; e, 3F-
nlacZ-9), including the forming trapezius (T), lattisimus dorsi (L), deltoid (D), and forelimb extensor muscles (E). The majority of skeletal
muscles express the 3F-nlacZ-2E transgene at E14.5 (f). DRG, dorsal root ganglia; RP, roof plate; CP, choroid plexus; arrowhead (d), 3F-
nlacZ-2I transgene expression initiating in the temporalis muscle; asterisk, ectopic activation of the 3F-nlacZ-2I transgene in ectoderm
in the nasal region (d); FL, forelimb region showing ectopic activation of the 3F-nlacZ-2 transgene (b).
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FIG. 6. Fetal activation of MLC3F transgenes. (a) Histological analysis of transgene expression in skeletal muscle of a 3F-nlacZ-9 fetus
at E14.5. Transgene expression is detected after X-gal treatment in a subset of skeletal muscles at this stage (diaphragm, D; body-wall
muscles, arrows) whereas others are b-galactosidase negative (intercostal muscles, arrowheads). The 3F-nlacZ-9 transgene is expressed at
a high level in myocardial cells (A, atria). (b) The 3F-nlacZ-2E transgene is expressed in all skeletal muscles at E14.5. In situ hybridization
to endogenous MLC3F transcripts (c) and MLC1F transcripts (d) at E15.5; the MLC3F probe detects only processed MLC3F transcripts,
whereas the MLC1F probe recognizes unspliced MLC1F transcripts resulting in a nuclear signal. Higher levels of MLC3F transcripts are
detected in those muscles which ®rst activate the 3F-nlacZ-9 transgene. L, lung. Scale bar: 100 mm.
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FIG. 7. MLC3F transgene expression at late fetal stages. X-gal-stained skinned fetuses of 3F-nlacZ-9 (left) and 3F-nlacZ-2E (right) transgenic
lines at E18.5. At this stage the majority of skeletal muscles express both transgenes. T, trapezius (cervical part); D, deltoid; TB, triceps
brachii; E, forelimb extensor muscles; L, latissimus dorsi.
identi®ed at the MLC1F/3F locus. The intronic elementDISCUSSION
eluded detection in the enhancer-trap screen of DNA frag-
ments from the rat MLC1F/3F locus which led to theThe MLC1F/3F gene contains two independent promot-
identi®cation of the 3* enhancer (Donoghue et al., 1988),ers, MLC1F and MLC3F, which are activated at a high level
possibly because the intronic fragments used did not con-during embryonic and fetal stages of myogenesis, respec-
tain the complete 800-bp element; furthermore, we havetively. In this study we demonstrate that, in addition to a
observed that the activity of the intronic enhancer is3* enhancer active in embryonic, fetal, and adult skeletal
greater on the MLC3F promoter than on the MLC1F pro-muscle, there is a second enhancer in the ®rst intron which
moter used in the enhancer-trap assay (unpublished data).is active in adult but not embryonic skeletal muscle.
While the 3* enhancer is clearly an important regulatoryMLC3F transgenes under transcriptional control of this en-
element at this locus, our observations suggest that it ishancer are activated during fetal development in a dynamic
not essential for robust skeletal muscle-speci®c transcrip-pro®le of skeletal muscle gene expression which provides
tion from the MLC3F promoter in vivo. Indeed, the 3* andan in toto image of fetal myogenesis. Embryonic and fetal
intronic enhancers confer similar transgene expressionmyogenic programs therefore activate MLC1F/3F transcrip-
pro®les in adult muscle. Both enhancers are strong regula-tion through distinct regulatory elements.
tory elements, since all transgene-positive mice expressOur results show that high-level MLC3F transgene ex-
b-galactosidase; the strength of these enhancers is likelypression in adult skeletal muscle can be mediated by one
to contribute to the low variability in expression levelsof two alternative enhancers. These elements correspond
to the two DNase I-hypersensitive sites which we had observed between lines (see Rao et al. (1996) for a compar-
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FIG. 8. MLC3F transgene activation in primary and secondary ®bers during fetal myogenesis. Double immuno¯uorescence analysis of
cryosections through the tibialis anterior of an E17.5 3F-nlacZ-9 fetus. (a) All nuclei in the ®eld are identi®ed by Hoechst stain; (b) nlacZ-
positive nuclei are detected with an anti-b-galactosidase antibody (green). (c) Anti-perinatal (fast) myosin heavy chain antibody (red)
identi®es small secondary and large primary myotubes. (d) Double exposure of the images in (b) and (c) shows that the MLC3F-nlacZ-9
transgene is expressed both in the central nuclei of primary ®bers (arrows) and peripheral nuclei of secondary ®bers (arrowheads). Scale
bar: 20 mm.
ison of the strength of the 3* enhancer with other muscle- ®cation of regions within the MLC1F promoter which
effect position-dependent expression of the 1F-CAT-Especi®c enhancers). Both enhancers confer a higher level
of transgene expression in fast IIB than IIA and slow ®bers, transgene (Rao et al., 1996).
In the absence of either enhancer the 2-kb MLC3F pro-re¯ecting the endogenous MLC3F distribution (Wada and
Pette, 1993), and suggesting that cis-acting elements moter supports only extremely low-level reporter gene ex-
pression in the majority of skeletal muscles. Signi®cant lev-which restrict ®ber-type distribution may be present in
the 2-kb promoter region. Finally, both enhancers confer els of expression in particular head and neck muscles of 3F-
nlacZ-2 transgenic mice, including subregions of the masse-a high level of b-galactosidase expression in rostral mus-
cles, in contrast to 1F-CAT-E transgenic mice (Donoghue ter (R. Kelly, P. Zammit, and M. Buckingham, unpublished
data), suggest that transcriptional control in anterior mus-et al., 1991), suggesting that neither the 3* nor intronic
enhancer elements included in the 3F-nlacZ constructs cles may differ from trunk muscles (see Tajbakhsh et al.,
1997), consistent with studies in avian embryos demonstra-confer a rostrocaudal positional gradient on MLC3F tran-
scription. This observation is consistent with the identi- ting distinct embryological origins of these muscle groups
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(Noden, 1984; Wachtler and Jacob, 1986; Couly et al., 1992). rally distinct myogenic programs can act through separate
regulatory elements at a single locus. Furthermore, sinceIn contrast to skeletal muscle, the 2-kb MLC3F promoter
region can effect high-level reporter gene expression in car- embryonic myoblasts derived from MLC3F transgenic mice
containing the intronic enhancer do not activate thediac striated muscle from early embryonic stages (in two of
four transgenic lines). cis-acting elements conferring cardiac transgene on differentiation in culture, our results support
the hypothesis that fetal and embryonic myogenic programsMLC3F expression therefore lie in this extended MLC3F
promoter region. This conclusion is in agreement with the occur in myoblast populations which are intrinsically dif-
ferent.observations of McGrew et al. (1996) in 3F-CAT and 3F-
CAT-E transgenic mice containing a 628-bp rat MLC3F pro- 3F-nlacZ-9 and 3F-nlacZ-2I mice provide the ®rst exam-
ples of muscle-speci®c transgenes activated at E13.5. Themoter. Although these authors detected CAT expression in
pectoral and some limb muscles of mice from individual nlacZ reporter gene allows transgene activity to be moni-
tored in whole-mount embryos by X-gal staining, revealinglines with the promoter alone, skeletal muscle expression
was markedly augmented when the 3* enhancer was present a previously undocumented pro®le of muscle-speci®c gene
expression. Initiating in axial muscles, transgene activity(McGrew et al., 1996).
The major difference in reporter gene activity between rapidly spreads laterally as development proceeds, and by
E18.5 expression is approximately equivalent to that of themice containing the intronic and 3* enhancers is the time
at which the transgene is activated in skeletal muscle in 3F-nlacZ-2E transgene. Endogenous MLC3F transcripts, ex-
pressed at a low level throughout fetal muscle, are moreutero. 3F-nlacZ-2E transgenic mice activate nlacZ from E9,
whereas 3F-nlacZ-9 and 3F-nlacZ-2I mice do not activate abundant in those muscles that ®rst activate the 3F-nlacZ-
9 and 3F-nlacZ-2I transgenes, supporting our conclusionthe transgene in skeletal muscle prior to E13.5. Signi®-
cantly, the stages at which the two enhancers are activated that the 3* and intronic enhancers mediate differential accu-
mulation of MLC1F and MLC3F transcripts. The onset andcorrespond to the times at which MLC1F and MLC3F en-
dogenous transcripts accumulate. We therefore conclude subsequent pro®le of fetal activated MLC3F transgene ac-
tivity in skeletal muscle provides an in toto image of thethat the two enhancers at this locus mediate the differential
response to developmental cues resulting in early MLC1F developmental events associated with fetal myogenesis, and
it will be interesting to determine whether other late-upreg-and late MLC3F transcript accumulation. The DNA se-
quence of the 800-bp intronic element reveals the presence ulated muscle markers (such as MCK, Lyons et al., 1991)
follow the same expression pro®le. MRF4lacZ transgenicof six target motifs for bHLH proteins, transcription factors
which include the myogenic regulatory proteins MyoD, my- mice also activate reporter gene expression at fetal stages
(although 2±3 days later than 3F-nlacZ-9 mice); in one lineogenin, myf-5, and MRF4. These proteins have been shown
to be key activators of skeletal muscle-speci®c transcription the spinotrapezius muscle is the only skeletal muscle ex-
pressing the transgene at E15.5 (Patapoutian et al., 1993).(Weintraub et al., 1991). The 3* enhancer also contains E-
box motifs which contribute to enhancer activity in vitro In contrast to 3F-nlacZ-9 mice this remains the only ex-
pressing muscle at birth.and in vivo (Wentworth et al., 1991; Rao et al., 1996). Myo-
genic bHLH expression pro®les, however, suggest that these Endogenous MLC3F expression has been shown to be
nerve dependent in avian and mammalian embryos, in con-regulatory factors alone are unlikely to mediate differential
activation of the two enhancers (Lyons and Buckingham, trast to MLC1F expression (Merri®eld and Konigsberg,
1987; Barton et al., 1989). Fetal activation of the 3F-nlacZ-1992). Experiments are in progress to characterize nuclear
factors which interact with the intronic enhancer. 9 and 3F-nlacZ-2I transgenes occurs concomitantly with
innervation and the generation of secondary myotubes. InIt has been demonstrated that embryonic and fetal muscle
cells follow distinct myogenic programs in primary cultures the hindlimb, anterior crural muscles are innervated and
express these transgene markers prior to posterior musclesof avian, rodent, and human myoblasts (Haushka, 1974;
Stockdale and Miller, 1987; Vivarelli et al., 1988; Smith and (Ontell and Kozeka, 1984; R.K., P.Z., and M.B., unpublished
data); innervation may therefore contribute to fetal activa-Miller, 1992; Stockdale, 1992; Pin and Merri®eld, 1993).
These studies have shown that embryonic and fetal myo- tion of the intronic enhancer. Although coincident with
secondary myotube formation, expression of the 3F-nlacZ-blasts have different morphological properties and growth
requirements, and differentiate in vitro to generate myo- 9 transgene is not exclusive to secondary myotubes since
b-galactosidase-positive nuclei are found in both primarytubes with distinctive MHC phenotypes. Embryonic and
fetal myoblasts are thus likely to represent distinct lineages and secondary ®bers in the tibialis anterior at E17.5; other
fetal activated muscle markers such as perinatal MHC pro-predisposed toward different developmental fates. Studies
of skeletal muscle gene expression patterns during develop- tein are also expressed in both secondary (high level) and
primary ®bers (low level) at this stage of development (seement suggest that different myogenic programs also exist in
vivo (see Lyons and Buckingham, 1992). Our results con®rm Fig. 8; Condon et al., 1990). The diversity of adult muscle
®ber types originates during fetal development (see Kellythat distinct embryonic and fetal programs of myogenic dif-
ferentiation operate during development. Analysis of the and Rubinstein, 1994); analysis of the MLC3F transgenes
described here suggests that gene activation through eitherexpression pro®les of MLC3F transgenes containing either
the 3* or intronic enhancer demonstrates that these tempo- embryonic or fetal myogenic programs can result in a simi-
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